BPI-3016
Source BPI-3016 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
BPI-3016 is a newly engineered human glucagon‑like peptide‑1 (GLP‑1) analogue designed for the treatment of type 2 diabetes mellitus. Structural modifications give it high resistance to dipeptidyl peptidase‑IV (DPP‑IV) and extend its circulating half‑life, allowing the potential for once‑weekly dosing. Preclinical studies in diabetic mice and cynomolgus monkeys report sustained reductions in fasting and post‑prandial glucose, weight loss, and improved beta‑cell function.
Mechanism of Action
BPI-3016 acts as an agonist at the GLP‑1 receptor, preserving the affinity of native GLP‑1 for the receptor. Binding triggers activation of adenylate cyclase and a rise in intracellular cyclic adenosine monophosphate (cAMP), which enhances glucose‑dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. The analogue’s resistance to DPP‑IV cleavage prolongs its receptor‑mediated signaling compared with unmodified GLP‑1.
What the Research Shows
In vitro assays demonstrated that BPI‑3016 retains GLP‑1 receptor binding affinity and stimulates cAMP production similarly to native GLP‑1. Pharmacokinetic testing in diabetic cynomolgus monkeys showed a half‑life exceeding 95 hours after a single dose. Efficacy was evaluated in ob/ob mice, db/db mice, and spontaneous diabetic cynomolgus monkeys, where a single administration lowered fasting and post‑prandial plasma glucose for up to one week. Repeated once‑weekly injections for seven weeks produced sustained glucose control, reduced body‑mass index and body‑fat, improved glucose tolerance, and exhibited insulinotropic effects, indicating potential benefits for beta‑cell preservation.
Reported Benefits
Preclinical data suggest BPI‑3016 can provide prolonged glucose lowering with a dosing interval of once weekly, reducing the injection burden compared with daily GLP‑1 therapies. The analogue also appears to promote weight loss and improve beta‑cell mass in animal models, which are desirable outcomes for managing type 2 diabetes. Its resistance to DPP‑IV may enhance stability and therapeutic consistency.
Limitations of the Evidence
All reported findings are limited to in vitro experiments and animal studies; no human clinical trials have been published. Consequently, efficacy, optimal dosing, and long‑term safety in patients remain unknown. Pharmacokinetic and pharmacodynamic profiles were characterized only in diabetic cynomolgus monkeys, which may not fully predict human responses. Potential immunogenicity or off‑target effects have not been evaluated.
Safety Considerations
The abstract does not describe adverse events or toxicology outcomes in the animal studies, so safety in humans cannot be inferred. As with other peptide therapeutics, injection‑site reactions, gastrointestinal symptoms, or pancreatogenic effects are possible, but these remain speculative for BPI‑3016 until formal safety assessments are conducted.
How It Is Administered
BPI‑3016 was administered by injection in the preclinical studies, with pharmacokinetic data derived from subcutaneous dosing in monkeys. The formulation is designed to be long‑acting, supporting a once‑weekly injection schedule in future clinical use, although exact dosing regimens have not been defined.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowDing L, et al.2017-01-01T00:00:00.000000Z
Frequently Asked Questions
What makes BPI‑3016 different from existing GLP‑1 drugs?
BPI‑3016 incorporates structural changes that markedly increase resistance to DPP‑IV degradation and extend its half‑life to over 95 hours in monkeys, enabling the possibility of weekly rather than daily injections.
Has BPI‑3016 been tested in people?
No. The only published data are preclinical, involving cell‑based assays, diabetic mouse strains, and diabetic cynomolgus monkeys. Human clinical trials have not yet been reported.
What benefits were observed in animal models?
A single dose lowered fasting and post‑prandial glucose for up to a week, and weekly dosing for seven weeks improved glucose tolerance, reduced body‑mass index and body‑fat, and showed insulin‑stimulating effects, suggesting potential weight‑loss and beta‑cell benefits.
Are there any known safety concerns?
The published study does not detail adverse effects. Safety in humans is therefore unknown, and typical peptide‑drug cautions—such as injection‑site reactions or gastrointestinal upset—remain speculative.
How would BPI‑3016 likely be given to patients?
In the animal studies the compound was delivered by injection, and its long‑acting design is intended for once‑weekly subcutaneous administration, pending further development and clinical testing.
What is BPI-3016?
BPI-3016 is a newly engineered human glucagon‑like peptide‑1 (GLP‑1) analogue designed for the treatment of type 2 diabetes mellitus. Structural modifications give it high resistance to dipeptidyl peptidase‑IV (DPP‑IV) and extend its circulating half‑life, allowing the potential for once‑weekly dosing. Preclinical studies in diabetic mice and cynomolgus monkeys report sustained reductions in fasting and post‑prandial glucose, weight loss, and improved beta‑cell function.